Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates.

Differential scanning calorimetry and powder X-ray diffraction studies have been carried out with amorphous coprecipitates of indomethacin and poly(vinylpyrrolidone), PVP, to measure the glass transition temperature, Tg, as a function of mixture composition and the nonisothermal and isothermal crystallization of the indomethacin. Values of Tg as a function of mixture composition followed the ideal Gordon-Taylor equation up to about 50% w/w PVP. Inhibition of crystallization occurred at levels as low as 5% PVP and very significant inhibition was observed at and above 20% PVP. Inhibition of crystallization of indomethacin in the absence of PVP required a storage temperature 40-50 degrees C below Tg, whereas comparable inhibition with PVP was observed at storage temperatures 5 degrees C above Tg. This suggests that the inhibition of indomethacin crystallization by PVP may involve mechanisms other than just the general antiplasticizing effect (raising Tg) by PVP.

[1]  S. Mehta,et al.  Effect of polyvinylpyrrolidone on the crystallinity and dissolution rate of solid dispersions of the antiinflammatory CI-987 , 1994 .

[2]  T. Nagai,et al.  Stabilization of Amorphous State of Indomethacin by Solid Dispersion in Polyvinylpolypyrrolidone , 1983 .

[3]  S. Yamamura,et al.  Glassy state of pharmaceuticals. III. Thermal properties and stability of glassy pharmaceuticals and their binary glass systems. , 1989 .

[4]  George Zografi,et al.  The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state , 1990 .

[5]  W I Higuchi,et al.  Dissolution rates of high energy sulfathiazole--povidone coprecipitates II: characterization of form of drug controlling its dissolution rate via solubility studies. , 1976, Journal of pharmaceutical sciences.

[6]  J. Carstensen,et al.  Chemical stability of indomethacin in the solid amorphous and molten states. , 1993, Journal of pharmaceutical sciences.

[7]  Bruno C. Hancock,et al.  Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. , 1994, Journal of pharmaceutical sciences.

[8]  A. Saleki-Gerhardt,et al.  Assessment of disorder in crystalline solids , 1994 .

[9]  Yrjö H. Roos,et al.  Plasticizing Effect of Water on Thermal Behavior and Crystallization of Amorphous Food Models , 1991 .

[10]  T. Nagai,et al.  Stability and several physical properties of amorphous and crystalline form of indomethacin. , 1980, Chemical & pharmaceutical bulletin.

[11]  S. Riegelman,et al.  Pharmaceutical applications of solid dispersion systems. , 1971, Journal of pharmaceutical sciences.

[12]  M. Summers,et al.  The effect of wetting agents on the dissolution of indomethacin solid dispersion systems , 1986 .

[13]  M. Summers,et al.  Effect of primidone concentration on glass transition temperature and dissolution of solid dispersion systems containing primidone and citric acid. , 1977, Journal of pharmaceutical sciences.

[14]  K. Ishihara,et al.  The nucleation of metastable phases from undercooled liquids , 1985 .

[15]  N Kaneniwa,et al.  A kinetic study of the crystallization process of noncrystalline indomethacin under isothermal conditions. , 1988, Chemical & pharmaceutical bulletin.

[16]  J. Plaizier-Vercammen,et al.  Interaction of povidone with aromatic compounds II: Evaluation of ionic strength, buffer concentration, temperature, and pH by factorial analysis. , 1981, Journal of pharmaceutical sciences.